| Bioactivity | SAK3 is a potent T-type voltage-gated Ca2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice[1]. SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity[2]. | ||||||||||||
| Invitro | SAK3 (0.01-10 nM) significantly enhances Cav3.1 or Cav3.3 currents in neuro2A cells ectopically expressing Cav3.1 or Cav3.3, respectively[1]. Cell Viability Assay[2] Cell Line: | ||||||||||||
| In Vivo | Acute SAK3 (0.5 mg/kg) oral administration promotes acetylcholine (ACh) release in hippocampal CA1 via T-VGCC stimulation via enhancing T-type Ca2+ channel[1]. Animal Model: | ||||||||||||
| Name | SAK3 | ||||||||||||
| CAS | 1256269-87-0 | ||||||||||||
| Formula | C20H23N3O4 | ||||||||||||
| Molar Mass | 369.41 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yasushi Yabuki, et al. Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer. Neuropharmacology. 2017 May 1;117:1-13. [2]. Jing Xu, et al.T-Type Ca2+ Enhancer SAK3 Activates CaMKII and Proteasome Activities in Lewy Body Dementia Mice Model. Int J Mol Sci. 2021 Jun 8;22(12):6185. |